[ad_1]
Synopsis
A 16% CAGR in revenue and 17% CAGR in Ebitda over the last three years, and an Ebitda margin of over 30%. Add to it a good quality-compliance record. The company’s performance has been robust. It is now looking to expand capacity, portfolio, and geographical presence, but can it sustain its run?
Active pharmaceutical ingredients (APIs) are the backbone of pharma industry. When the pandemic struck, cracks in the pharma supply chain were exposed, especially the high dependence on China for APIs and other key raw materials. This brought the not-so-glamorous API sector into the limelight. Over the last one year, API makers in India like Divi’s Laboratories, Laurus Labs, Aarti Drugs, Granules India, and Solara Active Pharma Sciences have not
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link